evenimente-corporate.ro 34 (1/) by Versa Media - Issuu

Aggressive cancer unknown primary, Studiu clinico-patologic al tumorilor ovariene - experienţa de un an într-un centru medical

Abstract Rezumat Bone metastases BM are experienced nearly by one of two of all cancer patients either at presentation or during the disease course. As a fundamental rule, because treatment of BM usually aims to palliate, the cardinal objectives of treatment should incorporate the attainment of a rapid and durable pain relief with preserved mobility and functionality without causing significant toxicity. The present article will exclusively focus on the role of RT in the management of BM with a specific emphasis on the ongoing debate of fractionation and total dose schemes.

Bone tumors are heterogeneous neoplasms, comprising a large spectrum of entities, both benign and malignant. One of the greatest challenges regarding bone and aggressive cancer unknown primary tissue pathology is highlighting osteoblastic differentiation in malignant lesions.

From the numerous osteoblast-specific markers previously aggressive cancer unknown primary in the hpv genital wart, only osteocalcin, osteonectin and RANK have been used in histology studies. Giant cell tumour of the bone is a special entity, in the category of intermediate tumors, locally aggressive and rarely metastasising. It is also known to become malignant. Specific markers for giant tumor of the bone are p63 and RANK, the latter being an osteoblastic marker.

We investigated the expression of the quoted recent emerged markers, p63, CD56 and SATB2, in 23 bone and soft tissue primary and secondary neoplasms by constructing a tissue microarray paraffin block, and we analysed the impact of using them as a diagnostic marker in current practice.

Translation of "cancer pe" in Romanian

Tumorile osoase sunt neoplasme eterogene, cu­prin­zând un spectru larg de entităţi, atât benigne, cât şi maligne. Una dintre cele mai mari provocări privind patologia osoasă şi a ţesuturilor moi evidenţiază diferenţierea osteoblastică în leziunile maligne. Dintre numeroşii markeri osteoblastici specifici descrişi anterior în literatură, numai osteocalcinul, osteonectina şi RANK au fost utilizaţi în studiile de histologie.

Tumorile cu celule gigantice ale oaselor sunt o entitate specială, în categoria tumorilor intermediare, la nivel local agresiv şi aggressive cancer unknown primary cu metastaze.

aggressive cancer unknown primary human papillomavirus world health organization

Este, de asemenea, cunoscut faptul că pot deveni maligne. Markerii specifici pentru tumora gigantică a osului este p63 şi RANK, acesta din urmă fiind un marker osteoblastic. Am investigat expresia markerilor recurenţi, p63, CD56 şi SATB2, în 23 de neoplasme primare şi secundare ale cancerelor osoase şi ale ţesuturilor moi prin construirea unui bloc de parafină microarray şi am analizat impactul utilizării acestora ca marker de diagnostic în practica curentă.

Cuvinte cheie SATB2 tumoră de celule gigantice diferenţiere osteoblastică Introduction In bone and soft tissue pathology practice, diagnosing malignant tumors like osteosarcoma is a difficult task, especially in biopsy samples 1. But an accurate decision is crucial, as chemotherapy and surgery approaches are fundamentally distinct for different aggressive cancer unknown primary types Immunohistochemistry has been assessed as an additional tool to the morphological investigation, and abdominal cancer tumours to diagnostic immunohistochemistry, a series of osteoblast-specific markers have been described in the literature, such as osteocalcin, osteonectin, bone morphogenetic protein BMPCOL-I-C peptide, bone sialoprotein, bone glycoprotein, 75 decorin, osteopontin, proteoglycans I and II, type I collagen and RANK, but only osteocalcin and osteonectin have been used in diagnostic immune histologic studies, without a special resonance in clinical practice 5.

Sinonimele și antonimele metastatic în dicționarul de sinonime Engleză

CD56 is a homophilic binding glycoprotein with a role in cell-cell adhesion. As an IHC marker, its main uses are in hematopoietic disorders, as aggressive cancer unknown primary marker of NK cells, for detecting residual myeloma or differentiate plasma cells in myeloma 10 from reactive plasmacytosis. Hughes, based on previous evidence of CD56 expression in osteoblast lineage, aggressive cancer unknown primary a study which concluded that CD56 may be a cancer de piele efecte important molecule in osteoblast function, and its expression is consistently strong in normal and neoplastic osteoblasts.

InKallen detected p63 expression papillomavirus recombinant vaccine osteoblastic tumors Previously, p63 had been known as a member of p53 gene family 12but without being a tumor suppressor gene.

Isoform deltaNp63 inhibits the transcription activation of p53 gene Then, inHornick suggested SATB2 as a potential marker for osteoblastic differentiation in bone and soft tissue tumors.

It encodes at least six different proteins with different biologic functions 9. SATB2 — known as special AT-rich sequence-binding protein 2 — is aggressive cancer unknown primary AT-rich DNA-binding protein that binds to nuclear matrix attachment regions involved in transcriptional regulation and chromatin remodeling Initial studies showed that SATB2 protein is expressed in colon and rectum tissue and tumors 15brain, branchial arches and osteoblast-lineage cells 16,17kidney, bladder 18some lymphoid cells and ovarian tumors Despite been identified in multiple tissues, it has not been thoroughly investigated as a potential neoplastic marker in bone and soft tissue tumors.

Înțelesul "metastatic" în dicționarul Engleză

Our purpose was to study the potential diagnostic applications of the three quoted antibodies as immunohistochemical markers in bone and soft tissue pathology, as well as evaluating positive expression scores and artefactual staining patterns.

Materials and method We searched the Foişor Hospital database, for all the bone and soft tissue tumors from to and encountered 39 cases Table 1 and Table 2. Table 1. Diagnosis and clinical features of the primary tumors Table 2. Diagnosis and clinical features of the metastatic tumors The tumors were subtyped according to diagnosis in 23 primary bone tumors benign and aggressive cancer unknown primary as follows Figure 1 : two fibrosarcomas, two osteosarcomas, seven chondromas, ten giant cell tumors GCT; two of them malignantone chondromyxoid fibroma, one brown tumor; and 16 metastatic tumors: two lung carcinomas, five clear cell renal carcinoma, one prostate carcinoma, one colon adenocarcinoma, one hepatocarcinoma, two breast carcinomas, four unknown primary adenocarcinomas.

Figure 1. Chart representation of the studied lot The hematoxylin-eosin slides for all the cases were reexamined, by three independent pathologists.

Apasă pentru a vedea definiția originală «metastatic» în dicționarul Engleză dictionary.

Figure 2. TMA recipient paraffin block and donor block We constructed two tissue microarray paraffin blocks TMA using the technique 20,21as follows Figure 2.

All donor blocks for the study cases have been selected and the region of interest defined on aggressive cancer unknown primary paraffin wax block. After the initial review and selection, the donor blocks were arranged and kept in the order that is represented in the TMA.

The array construction was made manual and was accompanied by a computer file, containing the tissue block identification numbers. The TMA was divided into four rows designated by letters and six columns ordered by numbers. Two-mm diameter donor tissue core needles were sampled.

Tissue cores were punched from the predefined region, and then transferred to a recipient paraffin wax block, into a readymade hole. The obtained paraffin blocks were incubated and processed as usual Figure 3.

Traducerea «metastatic» în 25 de limbi

Figure aggressive cancer unknown primary. TMA 2 mm tissue samples, HE stain For the immunostaining, we followed the indirect protocol for paraffin embedded tissue sections. The immunoreactive score IRS uses a range of as a product of multiplication between positive cells proportion score and staining intensity score Table 3. The immunoreactive score was broadly used for the expression of a wide spectrum of IHC markers The intensity of the reaction was variable, positive expression intensity ranging from weak signal 1 to strongly positive 3.

SATB2 was not detected in any adult normal non-osteoblastic tissue. Instead, we had experimented cases aggressive cancer unknown primary nucleolar artefactual staining. Figure 4. Tumor tissue array consisting of 23 tumor tissue samples stained for SATB2 — whole slide aggressive cancer unknown primary a. Table 4. IHC expression in bone tumors for p63, CD56 and SATB2 Of the 16 metastatic tumors two lung carcinomas, five clear cell renal carcinoma, one prostate carcinoma, one colon adenocarcinoma, one hepatocarcinoma, two breast carcinomas, four unknown primary adenocarcinomas in our studyonly the colorectal carcinoma showed significant labeling of the nuclear region, thus confirming the literature data Discussion and conclusions The aim of the study was to compare the potency of markers to fulfill an objective classification of osteoblastic differentiation in mesenchymal tumors.

Of these, SATB2 showed the aggressive cancer unknown primary numbers of cells marked and the highest intensity of the signal, while the CD56 showed the lowest numbers of marked cells.

A clinical-pathological study of ovarian tumors - one-year center experience

P63 lack of reactivity with high grade osteosarcoma makes it useful only for bone giant cell tumors and, when needed, as an indirect control for SATB2 positive tumors. While SATB2 can be considered neither a sensitive marker nor a specific one, it can become a valuable tool in diagnosing mesenchymal tumors in association with p63 and CD As from Table 4 and Figure 5, using p63 is highly valuable in IHC staining diagnosis of giant cell tumors, while SATB2 and CD56 are more useful in the diagnosis of aggressive osteosarcomas and malignancy in giant cell tumors.

Figure 5. The aspect was mentioned before in literature, but it was not investigated to our knowledge. The presence of a homogeneous форекс торговля в банке staining pattern associated with a nucleolar staining pattern in the same tumor suggests that this should not be considered a mere artifact and deserves further investigation.

Conflict of interests: The authors declare no conflict aggressive cancer unknown primary interests. Multidisciplinary approach to osteosarcoma.

gastric cancer lung metastasis cancer de piele la maini

Acta Orthop Belg. Therapeutic approach of primary bone tumours by bisphosphonates. Curr Pharm Des. Therapeutic strategies for treating osteolytic bone metastases. Drug Discov Today. Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther. Arch Biochem Biophys. Mol Med Rep.

aggressive cancer unknown primary cancer cerebral nivel 3

Am J Pathol. SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumours. Nuclear p63 expression in osteoblastic tumors.

Directory of Research Journals Indexing

Role of deltaNp63 pos CD44v pos cells in the development of N-nitroso-tris-chloroethylurea-induced peripheral-type mouse lung squamous aggressive cancer unknown primary carcinomas. Cancer Sci. Arch Pathol Lab Med.

  • evenimente-corporate.ro 34 (1/) by Versa Media - Issuu
  • Дело в том, что АНБ не только существовало, но и считалось одной из самых влиятельных правительственных организаций в США и во всем мире.

  • Journal Volume Details

Aggressive cancer unknown primary Cortex N Y N The role of SATB2 in skeletogenesis and human disease. Cytokine Growth Factor Rev. Hum Pathol. Am J Surg Pathol. Jawhar NMT. Tissue Microarray: A rapidly evolving diagnostic and research tool.

  • cancer pe - Translation into Romanian - examples English | Reverso Context
  • Studiu clinico-patologic al tumorilor ovariene - experienţa de un an într-un centru medical
  • Hpv virus natural cure
  • Simptome cancer osos picioare
  • Papilloma virus contagios
  • The aim of this study is a retrospective analysis of the spectrum of ovarian tumors: statistics, epidemiology and pathological features, based on one-year experience in our hospital.
  • Unfortunately, it does not have specific signs and symptoms, being associated with an aggressive evolution and a poor prognosis if left untreated.

Ann Saudi Med. Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer.

Studiu clinico-patologic al tumorilor ovariene - experienţa de un an într-un centru medical

Remmele W, Stegner HE. Ileal neuroendocrine tumors show elevated activation of mammalian target of rapamycin complex.

J Surg Res.

These examples may contain colloquial words based on your search. Translation of "cancer pe" in Romanian Suggest an example Hurthle cell cancer may be more aggressive than other types of thyroid cancer. Cancerul cu celule Hurthle poate fi mai agresiv decât alte tipuri de cancer tiroidian. Description:- Pe Invisible Scanner poti afla usor cine e invizibil pe messenger. Pe Invisible Scanner poti afla usor cine e invizibil pe messenger.

Am J Clin Pathol.